Investigating how GLP-1R agonists can help treat asthma in lean and obese patients
GLP-1R agonist immune targets in lean and obesity-associated asthma
This study is looking at whether a type of medication already used for diabetes and weight loss can also help people with asthma by reducing inflammation in their airways, and it will involve patients to see how well it works for easing asthma symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-10856599 on NIH RePORTER |
What this research studies
This research explores the potential of glucagon-like peptide-1 receptor (GLP-1R) agonists, which are already approved for treating type 2 diabetes and obesity, as a new treatment for asthma. The study aims to uncover the specific immune mechanisms through which these agents reduce airway inflammation, particularly in both lean and obese individuals. By examining how GLP-1R signaling affects immune cell function, the research seeks to enhance the clinical application of these medications for asthma management. Patients may be involved in trials that assess the effectiveness of GLP-1R agonists in alleviating asthma symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with asthma, particularly those who are lean or obese.
Not a fit: Patients with asthma who do not have a lean or obese body type may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for asthma patients, improving their quality of life and reducing inflammation.
How similar studies have performed: Previous studies have shown promise in using GLP-1R agonists for asthma treatment, indicating a potential for success in this novel application.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Cahill, Katherine N — Vanderbilt University Medical Center
- Study coordinator: Cahill, Katherine N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.